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Summary Stochastic models oftumorigenesis have been developed to investigate the implications of experimental data on tumour induction
in wild-type and p53-deficient mice for tumorigenesis mechanisms. Conventional multistage models in which inactivation of each p53 allele
represents a distinct stage predict excessively large numbers of tumours in p53-deficient genotypes, allowing this category of model to be
rejected. Multistage multipath models, in which a p53-mediated pathway co-exists with one or more p53-independent pathways, are
consistent with the data, although these models require unknown pathways and do not enable age-specific curves of tumour appearance to
be computed. An alternative model that fits the data is the 'multigate' model in which tumorigenesis results from a small number of gate-pass
(enabling) events independently of p53 status. The role of p53 inactivation is as a rate modifier that accelerates the gate-pass events. This
model implies that wild-type p53 acts as a 'caretaker' to maintain genetic uniformity in cell populations, and that p53 inactivation increases the
probability of occurrence of a viable cellular mutant by a factor of about ten. The multigate model predicts a relationship between the time
pattern of tumour occurrence and tumour genotype that should be experimentally testable. Stochastic modelling may help to distinguish
'gatekeeper' and 'caretaker' genes in othertumorigenic pathays.
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Tumorigenesis is usually considered to be a multistage process in
which a single cell experiences a series oftumorigenic events (muta-
tions in a broad sense), not necessarily in an ordered sequence,
leading to malignant transformation. The stages of the process,
thought to be between 2 and 10 in numberdepending on tumourtype
(Renan, 1993; Vogelstein and Kinzler, 1993) are nowadays believed
to be the activations of oncogenes and inactivations of tumour-
suppressor genes, resulting inprogressive loss ofgenetic control over
cell proliferation, death or differentiation in a particular lineage. It is
recognized that alternative genetic pathways may exist leading to the
same malignant phenotype (multipath multistage concept) (Tan,
1991; Sherman and Portier, 1994). Stochastic models of multistage
tumorigenesis have a rich history and have been valuable in relating
specific biological hypotheses to the age distribution and other
outcomes ofthetumorigenic process (Tan, 1991). A strikingexample
was the statistical modelling used by Knudson and associates
(Knudson, 1971; Knudson, 1996) in their two-stage model for the
genesis ofretinoblastoma. The model successfully predicted the high
risk, earlier age distribution and tumour multiplicity (bilaterality) in
individuals inheriting a defective copy of the Rb gene (familial
retinoblastoma). This triad of features (high incidence, earlier onset
andpropensity to tumourmultiplicity) ischaracteristic ofamultistage
model for which the number of stages has been reduced by inheri-
tance of a tumorigenic genetic aberration. The original retino-
blastoma model has been developed by Moolgavkar and associates
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and extended to more than two stages (Moolgavkar and Venzon,
1979; Moolgavkar and Knudson, 1981) and now provides the main
paradigm for mathematical theories of multistage tumorigenesis. In
this paper, we will consider the applicability of such models to the
occurrenceoftumorigenesis inp53-deficienttransgenic miceandwill
seeknewbiological insights from the mathematical analysis.
Tumorigenesis in p53-deficient mice
The current high level of interest in p53-mediated tumorigenesis
derives from the seemingly causal involvement ofp53 dysfunction
in a wide spectrum of human and animal tumours and its role in
cellular transformation in vitro (Hollstein et al, 1991; Lane, 1994).
Investigation of specific pathways of tumorigenesis has been
greatly helped by the development oftransgenic mouse models in
which specific genes have suffered 'knock-out', thus enabling
their causal role to be evaluated (Fowlis andBalmain, 1993). In the
case of p53, transgenic mice are available in which each somatic
cell retains both alleles of functional p53 gene (wild type or
p53+/+) or a single functional allele (p53 null heterozygote or
p53+/-) or in which both alleles are lost or disrupted (p53 null
homozygote or p53-/-) (Donehower et al, 1992). These mice are
of identical genotype (i.e. belong to the same strain) and differ
only in the p53 status of all their somatic cells. These transgenic
models provide potent tools for the unravelling of p53-mediated
tumorigenic pathways. On the multistage single-pathway model, if
N discrete stages are ordinarily required for tumorigenesis in
p53+/+ mice, then N-1 stages will be required in p53+/- mice and
N-2 stages in p53-/- mice. This allows the number of stages to
become a controlled variable in tumorigenesis experiments, a
possibility which did not exist until recently.
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Table 1 Statistics of tumour occurrence (all types) in two strains of wild-type and p53 deficient mice. [From reported data of
Donehower et al (1995).]
Genotype Tumour incidence (%) Tumour median latency (weeks)
129Sv 129Sv/C57B1 129Sv 129Sv/C57B1
p53+/+ 8 11 > 104 > 104
p53+/- 47 40 67 76
p53-/- 100 100 13 19
Experimental data are now available on the time of tumours
developing spontaneously in wild-type and p53-deficient mice.
The tumours are of several types, but the majority (in all geno-
types) are lymphomas, with sarcomas the next most frequent cate-
gory. Table 1, based on recent data of Donehower et al (1995),
shows that inactivation of a single p53 allele elevates tumour inci-
dence from about 10% (in p53+/+ mice) to about 45% (in p53+/-
mice); therefore the majority of tumours developing in p53+/-
mice are mediated by p53 inactivation. In p53-/- mice, the inci-
dence increases to 100%.
Therefore, whatever the role ofp53 may be in tumour develop-
ment in wild-type mice, we may be confident that p53 inactivation
provides the major route of tumorigenesis in p53+/- mice and is
almost the exclusive route in p53-/- mice.
Table 1 also shows that, as expected, tumours develop earliest in
the p53-/- mice and latest in those with the wild-type genotype. A
trend to tumour multiplicity has also been seen in the p53-deficient
mice, but this is of modest extent. From several reports (Harvey et
al, 1993; Hursting et al, 1994; Jacks et al, 1994; Kemp et al, 1994;
Purdie et al, 1994; Donehower et al, 1995), tumours are almost
always single in wild-type mice, multiple tumours (typically no
more than two) are occasionally seen in p53+/- mice and two to
four tumours are not uncommon in p53-/- mice, although
lymphomas in particular may be reported as 'generalized'; for
example Hursting et al (1994) recently reported a total of 67
tumours in 52 pS3-/- mice over a 48-week period, with more than
one tumour observed in 35% ofall tumour-bearing mice. However,
tumour multiplicity always remains in single figures and the
median number of distinct tumours at presentation is one for all
genotypes. We have considered whether these data may be accom-
modated by a single-pathway multistage model of conventional
type with inactivation of each p53 wild-type allele representing a
tumorigenic stage (Figure 1). The analysis is presented below.
STOCHASTIC MULTISTAGE SINGLE-PATH
MODEL
We have modelled spontaneous tumorigenesis in wild-type and
p53-deficient mice as a single-pathway multistage stochastic
process in which a generic 'stem cell' population follows a growth
kinetic pattem that is exponential from time of conception, but
slows in accordance with Gompertzian kinetics as the mouse
approaches maturity. Stem cells experience a series of mutations
corresponding to successive stages of a multistage tumorigenesis
model. In this analysis, inactivation of each p53 allele is repre-
sented as a distinct stage in the tumorigenic process, so p53+/-
genotypes require one less stage, and p53-/- genotypes two less
stages than wild-type genotypes, for malignant change to be
accomplished in a single stem cell.
Stem cell Differentiation/death
Self-renewal
One-stage > Differentiation/death
mutant
Self-renewal
Two-stage > Differentiation/death
mutant
3
gk-1
Self-renewal
k-i-stage Dfee mutant
> Differentiation/death
gk
Malignant cell
Detectable tumour
Figure 1 General structure of the multistage single-path model. A total of k
stages (generalized mutations) are required for the transition from stem cell
to malignant cell. No growth advantage is assumed for intermediate mutants
that have not yet achieved full malignant transformation
The mutation rate g is assumed to be the same for all stages. The
mathematics ofthe process is similar to the model of Moolgavkar
and Venzon (1979) and the analytic structure of the model used
here has been described elsewhere (Mao and Wheldon, 1995).
Briefly, forthemultistage model depicted inFigure 1, each stem
cell at division may reproduce, die or differentiate or experience a
mutation advancing it to the next stage ofthe model. Cells experi-
ence these competing processes independently. It should be noted
that only viable cells are counted in each mutational compartment.
The mutation rate in this context means the probability/unit time
of production of a viable cellular mutant and will be affected by
the death rate of mutants as well as by the rate of production of
genomic lesions in the original cell. Premalignant mutants are
taken to follow the same (exponential-Gompertzian) self-limiting
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Table 2 Tumour occurrence in mice of different genotypes as predicted bythree-, four- and five-stage single path models. The mutation rates were chosen to
give approximately 0.1-0.2 tumour incidence (i.e. fraction of mice developing tumours) in wild-type mice by 80 weeks. In this scenario, all tumours develop by a
route involving p53 inactivation
Genotype Three-stage model Four-stage model Five-stage model
(mutation rate = (mutation rate = (mutation rate =
7.5x10-8) 5x106) 1.65x10-4)
Tumours/mouse Tumours/mouse Tumours/mouse
16 weeks 80 weeks 16 weeks 80 weeks 16 weeks 80 weeks
p53+/+ 0.002 0.12 0.003 0.09 0 0.2
p53+/- 6.8 1.9x 102 0.26 45 0.03 19
p53-/- 3.3x 104 1.7x 105 5.5X 102 9.6x 103 9.4 9.1 x 102
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Figure 2 Predicted pattern of time of tumour development in mice of three
genotypes for (A) three-, (B) four- and (C) five-stage single-path models. In
each case, the mutation rates have been chosen to give 10-20% tumour
incidence in wild-type mice by 80 weeks; the models then predict excessively
rapid development of tumour in both p53-deficient genotypes. The vertical
broken lines in the diagrams show median latency of experimental tumours
[averaged data from Donehower et al (1995); Table 1]
growth pattern as unmutated stem cells, i.e. the premalignant
mutants have no growth advantage. However, each malignant cell,
once it exists, follows an unrestrained growth pattern (linear
birth-death process) until the tumour is large enough to be
detectable (106 malignant stem cells).
We investigated age dependence of the occurrence of tumours
and predicted tumour multiplicity by using computer simulation,
the simulation being continued for 600 days, i.e. close to the
Figure 3 General structure of multistage multipath model with p53-mediated
and p53-independent routes of tumorigenesis
mouse lifespan. This process is divided into two parts, i.e. the
conversion of a normal stem cell into a malignant cell and the
growth of each malignant clone to form a tumour. Ideally, each
malignant cell should be followed separately, but this becomes
prohibitive when the number ofmalignant cells generated is large.
In that case, the detection (or not) of a tumour is simulated as a
binomial distribution with probability PD(s, 600), obtained from
the linear birth-death process where s is the time when the malig-
nant cell is generated.
For wild-type genotypes, we have considered three-stage, four-
stage and five-stage models and have in each case chosen the muta-
tion rate to give approximately 10% tumour incidence in wild-type
mice by 600 days. The corresponding tumour incidence forp53+/-
and p53-/- mice then follow by subtracting one or two stages,
respectively, without changing the mutation rate. For presentation,
we have computed the number of tumours predicted to have
appeared by 16 and 80 weeks, close to the observedmedian latency
in p53-/- and p53+/- mice, in each ofthese situations.
Table 2 shows thatthree-, four- and five-stage models all predict
the early development oflarge numbers oftumours in both p53+/-
and p53-/- mice. Although observed numbers of tumours will
certainly be underestimates of the number destined to develop, it
hardly seems possible that the predicted thousands of tumours
could be reconciled with the typical observation ofone ortwo. The
corresponding curves ofage dependence oftumourappearance are
shown in Figure 2 and demonstrate much faster tumour develop-
mentpredicted by the model forboth p53-deficient genotypes than
occurs in practice. (The latent periods seen experimentally for
p53-deficient mice are also shown in Figure 2 for comparison.)
This discrepancy has been found to occur for all combinations of
model parameters giving 10% lifetime incidence of tumours in
wild-type mice; it appears to be a robust feature of this class of
model. We have also simulated a six-stage model (data not shown)
for which more modest number of tumours are predicted for
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Figure 4 Predicted pattern of time of p53-dependent tumour development for mice of three genotypes for the five-stage multipath model with (A) 100, (B) 60,
(C) 30, (D) 20 and (E) 10% of tumours in wild-type mice arising by the p53-dependent route. The vertical broken lines in the diagrams show median latency of
experimental tumours [averaged data from Donehower et al (1995); Table 1]
p53-/- mice (albeit with very high mutation rates), but the model
then under-predicted the tumour incidence for p53+/- mice. It is
evident that this will be a feature of all higher stage models. We
have concluded that it is not possible to accommodate data on
tumour incidence in wild-type and p53-deficient mice by the
classical multistage single-path model.
Multistage multipath model
Recently, several authors have considered an extension of the
multistage model that allows for the development of any type of
tumour by alternative multistage pathways involving different sets
of genes (Tan, 1991; Sherman and Portier, 1994). This concept is
Table 3 Predicted tumour development by the p53-mediated pathway in
wild-type and p53-deficient mice on a 5-stage model for p53-mediated
tumorigenesis with 20% of all tumours in wild-type mice developing by the
p53-mediated route and 80% by p53-independent pathways
Genotype Five-stage model
(Mutation rate = 7.5 x 10-6 ± 1.5 x 10-5)
p53-mediated tumours per mouse
16 weeks 80 weeks
p53+/+ 0 0.038
p53+/- 0.006 0.83
p53-/- 0.863 193
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Figure 5 General structure of the multigate model with a two-stage mutational rate-modifier pathway and with three gate-pass events required from stem cell
to malignancy
Table 4 Predicted tumour development in wild-type and p53-deficient mice on a three-gate model with two-stage modifier (p53
inactivation) pathway. On this model tumours may arise by the same gateway with or without p53 inactivation; the proportion having
inactivated p53 is shown in the second column
Genotype Three-gate model with two-stage modifier Proportion of all
tumours developing
(X=10-4±2x10-6,=10-6±2.5x10-, k=10) by80weekswith
Tumours/mouse inactivated p53
16 weeks 80 weeks
p53+/+ 0.0004 0.10 0.055
p53+/- 0.0015 0.91 0.92
p53-/- 0.56 375 1.00
illustrated in Figure 3. In the present context, this means that a
proportion oftumours in wild-type mice develop by pathways that
are independent ofp53 status and would have the same probability
of occurrence in p53-deficient mice. To investigate this, we have
rerun the multistage single path model on the assumption that only
a fraction, f, of the tumours developing in wild-type mice have
arisen by the p53-mediated pathway. It is then only the p53-medi-
ated tumours whose frequency is increased in the p53-deficient
genotypes. We have run three-, four- and five-stage models for a
range off-values and observed similarity with the experimental
data only for the five-stage model with f = 0.2 (i.e. 20% of all
tumours in wild-type mice developing by the p53-mediated
pathway). For f > 0.2, an excess of tumours are predicted for
p53-/- mice and forf < 0.2 a deficit of tumours in the p53+/-
genotype (Figure 4). The data forp53-mediated tumours forf= 0.2
are shown in Table 3.
The detailed age dependence of tumour development cannot be
computed on this model as the process of tumour development is
only defined mechanistically for the p53-mediated pathway - the
non-p53-mediated path has unspecified structure and parameters.
For this reason, Table 3 shows only the tumours developing by the
p53-mediated route; in the p53+/- and p53-/- (but not wild-type)
genotypes these will be the majority oftumours. Table 3 shows that
more reasonable tumour numbers may be calculated for each ofthe
genotypes, considering that the experimental latency time for
p53+/- mice is about 71 weeks and for p53-/- mice is about 16
weeks. This means that the multistage multipath model does seem
capable of being reconciled with most of the data. The need to
postulate altemative, as yetundefinedpathways, is an unsatisfactory
feature ofthe model, as is the inability to compute age-dependence
curves but does not mean this process could not occur in biological
reality. In the sections thatfollow, wewillconsideradifferentmodel
that incorporates recent thinking about the role of p53 and that
appears to accommodate the data in a more natural way.
A multigate model with two-stage modification of
mutation rate
In each of the preceding models, mutations occurred indepen-
dently and the rate of mutation at any stage was unaffected by
mutations that had already occurred at other stages. However, it is
a current hypothesis, termed by Lane (1992) the 'guardian of the
genome' concept, that p53 inactivation results in generally
increased mutation rates, i.e. wild-type p53 acts to confer genetic
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Figure 6 Predicted pattern of time of tumour development for mice of three
genotypes for the multigate model with two modifier stages (mutation rate =
10-4 per cell division) and three gate-pass events (mutation rate = 10-5 per
cell division) and a mutation rate modifying factor of 10. The vertical broken
lines in the diagrams show median latency of experimental tumours
[averaged data from Donehower et al (1995); Table 1]
stability. Similarly, on this model, p53 inactivation could lead to
increased survival of cellular mutants that would otherwise have
died (e.g. as a result ofp53-dependent apoptosis). We now wish to
consider how this idea may be incorporated in stochastic model-
ling and how well the model accommodates the data. To do this, it
may be useful to distinguish between mutations that are directly or
indirectly tumorigenic.
Directly tumorigenic mutations, whether these are oncogene
activations or inactivations of tumour-suppressor genes, are
'enabling' or obligatory events that must accumulate to a
minimum number, or possibly to one ofseveral altemative config-
urations, formalignant transformation ofthe affected cell. We may
consider that tumorigenesis requires a number of regulatory
'gates' to be passed and that a tumorigenic mutation of a direct
type alters a gateway gene and corresponds to a gate-pass event.
The gate-pass events are the stages of the multistage model.
However, indirect mutations are not enabling events in themselves
but modifiers of the tumorigenic mutation rate. This leads to a
multigate model of tumorigenesis with mutation rates under the
control ofrate-modifier genes. Mutated rate-modifier genes lead to
altered mutation rates in gateway genes. A similar concept has
been proposed by Loeb (1991), who has argued for the existence
ofa 'mutator phenotype' and by Sherman and Portier (1994), who
have termed such a process a 'multihit' model to distinguish it
from multistage. Very recently, Kinzler and Vogelstein (1997)
have proposed a distinction between 'gatekeeper' and 'caretaker'
genes whose inactivation contributes to tumorigenesis, either
directly orindirectly. However, the properties ofsuch models have
not yet been explored and it has not previously been applied to
p53-mediated tumorigenesis. The structure of a three-gate model,
associated with a two-stage modifieror 'caretaker' (p53-mediated)
pathway is depicted in Figure 5.
A feature of the model is that mutation of the gateway genes
alone (without modifier gene mutations) may lead to malignant
transformation, whereas modifier mutations cannot achieve trans-
formation without gate-pass events. Therefore, only aproportion of
tumours developing by this gateway will be associated with modi-
fier mutations. This proportion will depend on the numbers of
genes involved in the gateway and in the modifier pathway, and on
rates of mutation of modifier genes and of gateway genes, when
modifier mutations have or have not occurred. Generally, the
proportion of modifier-associated mutations will be low unless
there are more gates than modifier stages or unless the modifier
genes are themselves more prone to mutation than the gateway
a, 0c
o
.. m
0
E
as
a,
Co .C.
0
ca
0
a,
C
C.) CO
._ C,)
LO
QL
100 -
80 -
60 -
40 -
20 -
0 - _
0 10 20 30 40 50 60 70 80 90
Age (weeks)
Figure 7 Predicted proportion of p53 inactivation-associated tumours
appearing as a function of mouse age in the p53 wild-type and heterozygous
genotypes. 0, p53 (+ -) mice; V, p53 (+/+) mice
genes. The new model is more complex than the classical multi-
stage model; an investigation of its properties will be reported in
detail elsewhere. Here, we wish to establish whether this type of
model can account fortumourincidence datainp53-deficient mice.
To apply these concepts to tumorigenesis in p53-deficient mice,
we propose that p53 is a rate-modifying (caretaker) gene whose
inactivation requires two stages in wild-type mice and one-stage
inactivation in p53+/- mice; of course the gene is already inacti-
vated in p53-/- mice. In each genotype, the same number of
gateway gene mutations is required. Gateway genes have a base-
line mutation rate ,u when p53 function is maintained, which is
increased to mutation rate k,u when p53 function is lost. The muta-
tion rate for two-stage loss of p53 function is assigned the inde-
pendent value X. Computer simulations have been carried out for a
range ofvalues ofthe number ofgates in the model, for a range of
values of the mutation rates of the modifier genes and (indepen-
dently) the mutation rate of the gate-pass genes, and a range of
values of the modifying factor (the scaling factor for gate-pass
mutation rate). We have observed that better agreement with the
data is found when the modifier gene mutation rate is higher than
that of the gate-pass genes (implying that p53 is itself relatively,
genetically unstable). The modifying factor then has a value
around ten. Table 4 and Figure 6 show predicted data for three
mouse genotypes for this case. In support ofthis hypothesis, some
evidence suggests that after the loss of the first p53 allele, loss of
the second allele occurs more easily (Harvey et al, 1993). Further
experiments will be needed to confirm this possibility.
It can be seen that realistic predictions oftumour numbers in the
three genotypes can now be achieved. Notice that the mean tumour
number/mouse is now slightly less than 1 for p53+/- and p53-/-
mice by 80 and 16 weeks respectively, although large tumour
numbers would still be predicted for p53-/- mice by 80 weeks;
however, no such mice will survive to this time. The model parame-
ters are not uniquely defined by the available data and other combi-
nations ofgate number and mutation and modifying factors may be
possible. We will present a full description of the mathematical
properties ofthe multigate model in aforthcoming publication.
The model also provides predictions of the proportions of
tumours that occur in each genotype in association with p53 inac-
tivation; these are shown for tumours accumulated by 80 weeks in
the last column ofTable 4. We have also computed the proportion
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of p53 inactivation-associated tumours appearing as a function of
mouse age in the wild type and p53+/- genotypes and have
observed that this proportion shows a tendency to increase with
age (Figure 7), implying that p53 inactivated tumours will
be relatively over-represented among late-occurring tumours.
Comprehensive experimental data on this have not yet been
reported for p53-deficient mice. When this data is available, it will
provide a more stringent requirement that should enable a test of
the model and allow the parameters to be specified more precisely.
DISCUSSION AND CONCLUSIONS
The analysis has demonstrated a fundamental problem in the appli-
cation of the classic multistage model to spontaneous tumori-
genesis in p53-deficient mice. On a multistage model, with a
single pathway oftumorigenesis, the reduction in stage number by
one, resulting from germ line inheritance ofone ofthe tumorigenic
mutations, without change of mutation rate, results in a marked
increase in predicted tumour frequency. Transgenic mice have
provided a unique opportunity to test the prediction that the
inheritance oftwo tumorigenic mutations (inactivated p53 alleles),
corresponding to a reduction in stage number by two, would
produce an astronomical number of tumours per mouse. Our
analysis shows that this prediction applies for up to five stages
being required for tumorigenesis in wild-type mice.
This difficulty has been recognized previously. In 1990,
Vogelstein commenting on tumourincidence inhumanLi-Fraumeni
patients posed the question 'Why don't these patients develop more
tumours?' and commented 'Given the diverse tumours occurring in
Li-Fraumeni patients it would seem that many human cell types are
susceptible to the effect of inherited p53 mutations; yet the median
age oftumour development is over 30 years and the median number
oflifetime tumours is less than two' (Vogelstein, 1990). Vogelstein's
paradox also occurs for the double-defect p53-/- mice, which still
show no more than a few tumours per mouse, although thousands
would be predicted. This analysis has identified two categories of
explanation for this paradox. The first of these, the multistage
multipath model invokes a p53-independent pathway that exists in
parallel with ap53-mediated route oftumorigenesis. Only the latter
route is enhanced inp53-deficient genotypes. On this type ofmodel,
the mutation rates are independently fixed and these inherent rates
are not changed by p53 inactivation. We have found that a p53-
mediated five-stage pathway that provides 20% of the tumours in
wild-type mice is consistent with the data.
The second mechanism, which we have called the multigate
model, postulates a single pathway (or gateway) with several gate-
pass events (obligatory mutations) occurring at a rate that depends
onp53 status. We have not yet fully explored this category but have
observed that the data can be accommodated by a three-gate model
in which the gate-pass mutation rate is amplified by a factor of
about 10 when both p53 alleles are inactivated. It is also possible to
envisage combined models (multigate multipath) but the currently
available data do not require a combined model to be invoked.
It should again be noted that the present model does not distin-
guish a higher mutation rate in itself from higher probability of
survival ofmutants. It would therefore be consistent with a role for
p53 in DNA damage-mediated apoptosis provided the apoptosis
rate remained low (see below).
The multigate model differs from the multistage/multipath
model in postulating that p53 inactivation has a rate-modifying
role in a tumorigenesis pathway that can nevertheless proceed
independently of p53. Suppose, for example, that inactivation of
both Rb alleles are two enabling (gate-pass) genetic events in a
particular tumour type. Then we expect that some tumours will be
Rb doubly mutant (with intact p53) others will be Rb doubly
mutant with inactivated p53. However, no tumours will be found
to have suffered only p53 inactivation. The inactivation of p53
would therefore appear to be 'optional' in this mechanism of
tumorigenesis. The multistage multipath model requires that ifp53
is implicated in a tumorigenic pathway then any alternative
pathway not involving p53 will instead have to involve some other
genetic events (e.g. some genetic event additional to, or as an alter-
native to, the Rb inactivation considered in the example), i.e. p53
inactivation fulfils a role that is not 'optional' and would have to
be replaced. It is also a feature of the multigate model that p53
inactivation should precede at least one of the gate-pass events,
whereas on the multistage model p53 inactivation could just as
easily come last.
Of course, the main difference between the models is that
the multigate model is essentially a genetic instability model
and requires that p53 inactivation be a destabilizing event.
Experimental evidence on this is not wholly consistent at present,
with some workers reporting a significant increase in the mutation
rate at a particular locus (Havre et al, 1995; Xia et al, 1995) and no
difference being reported at other loci (Sands et al, 1995). In addi-
tion it is possible that the tumorigenic events that are enhanced
by p53 inactivation correspond to chromosome abnormalities
(Bouffler et al, 1995) or gene amplification (Livingstone et al,
1992; Yin et al, 1992) or other heritable events rather than tradi-
tional point mutations; also, that the influence of p53 inactivation
is confined to a restricted set of genes rather than being across the
genome. It is also possible that the main impact ofp53 inactivation
will be in relation to the processing of DNA damage and that its
role will be seen more clearly when mice of differing genotypes
are subjected to graded doses ofDNA-damaging agents.
These analyses have focused on the stage number and mutation
rates as major determinants of the tumorigenesis process. The
models considered have not assumed any proliferative advantage
of intermediate (premalignant) cells. However, it is possible that
intermediate cell proliferation could play a significant role in
tumorigenesis. Moolgavkar and Luebeck (1992) have proposed a
model for the role of the APC gene in colon cancer that entails
APC-mediated control of intermediate cell proliferation. A similar
role for p53 could be considered. In addition, Bodmer and
Thomlinson (1996), in a recent model, have emphasized the p53-
mediated control of apoptosis (preferential elimination of mutant
cells) rather than mutation rate itself. This is approximately equiv-
alent to the multigate model assumption of modification of muta-
tion rate ifthe apoptosis rate is ordinarily low (reduced apoptosis in
p53-deficient cells allowing the improved survival of mutants) but
ahigh rate ofapoptosis in wild type cells would lead indirectly to a
proliferative advantage ofp53 null cells (by imposing a higher loss
rate on p53+/+ and p53+/- cells). These variations have not yet
been fully explored in our analysis. Nevertheless, it seems clear
that the single-pathway multistage model forp53-mediated tumori-
genesis will have great difficulty in accommodating the experi-
mental data, and that alternatives to this model must be sought.
We will extend the analysis to radiation-induced tumorigenesis
in p53-deficient mice, for which some experimental data have
already been reported (Kemp et al, 1994). We will also extend the
model to deal with the development oftumours ofseveral different
types (e.g. lymphomas, sarcomas) thatmayhave different mutation
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rates or stage (gate) number or differing stem cell kinetics. We
expect that stochastic modelling of tumorigenesis in p53-deficient
mice will contribute to an understanding of tumorigenesis in
human Li-Fraumeni patients as well as to the role ofp53 in human
cancer more generally. The approach taken here should also prove
useful for analysis of tumorigenesis in other transgenic mouse
models especially in which, as in the MSH2-deficient (mismatch
repairdeficient) transgenic model (Reitmar etal, 1995), the genetic
defect would be expected to act as a modifier ofputative gate-pass
events (i.e. probable inactivation ofa caretaker gene). More gener-
ally, the analysis may help in the distinction between gatekeeper
and caretaker genes in many tumorigenic pathways.
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APPENDIX: MATHEMATICAL DEVELOPMENT OF
TUMORIGENESIS MODELS
Model 1: multistage single path model
This model (Figure 1) is a k-stage model of tumorigenesis with
cell proliferation and cell loss in all stages. Let Xo(t), X1(t),.
Xk 1(t) and Xk(t) represent the number of stem cells, one-stage
mutants, ..., k-I-stage mutants and malignantcells generated from
stem cells by time trespectively. At time t =0, X0(0) = 1, Xj(t) =0,
(j = 1, 2, ..., k), and T(O) =0. In a small time interval [t, t+At], aj-
stage mutant may:
(a)divide into twoj-stage mutants at rate bf(t)At+o(At);
(b)die (or differentiate) at rate d-(t)At+o(At);
(c)divide into onej-stage mutant and onej+ 1-stage mutant at
rate RjAt+o(At).i =0, 1, ..., k-i where a 0-stage mutant is a
stem cell and a k-stage mutant is a tumour cell, or
(d)stay unchanged.
All cells go through the above processes independently of other
cells. For the application to tumorigenesis in both wild-type and
p53-deficient mice, the single pathway is deemed to require inacti-
vation ofboth p53 alleles as obligatory stages.
Model 2: multistage multipath model
Figure 3 displays a two-pathway multistage model of tumori-
genesis. There are two possible routes for a normal cell to be trans-
formed into a malignant cell: (a) a p53-mediated route and (b) a
p53-independent route. A tumour develops independently by any
ofthe two pathways. The essential features ofeach pathway are as
described in model 1. The total rate oftumorigenesis is the sum of
the tumorigenesis rates occurring by each ofthe two pathways.
Model 3: multigate model with multistage modification
of mutation rate
In this model, p53 inactivation at both alleles acts as a modifier of
the rate of mutation of the tumorigenic states (gates). Figure 5
shows a three-gate/two-stage model as an example. Let X01(t),
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Figure 8 Predicted number of normal stem cells (X0), 1-stage mutants (X,) and 2-stage mutants (X2) by the three-stage model shown (A) over a 0-30 day time
scale, (B) over 0-600 day time scale (mouse lifespan). The family of curves in each case correspond to computer simulation for individual mice
X02(t), X03(t), XI(t), X,2(t), X,3(t), X21(t), X22(t), X23(t) and Y(t) repre-
sent the numbers of stem cells with p53+/+ (S/p53+/+), stem cells
with p53+/- (S/p53+/-), stem cells with p53-4- (S/p53-/-), gate-I
mutants with p53+/+ (G1I/p53+/+), gate-I mutants with p53+/-
(G1/p53+/-), gate-I mutants with p53-4- (Gl/p53-/-), gate-2
mutants with p53+/+ (G2/p53+/+), gate-2 mutants with p53+/-,
(G2/p53+/-), gate-2 mutants with p53-4- (G2/p53-/-), and malig-
nant cells generated from stem cells by time t respectively. At
time t = 0, XoI(t),
= 1, X02(t) = 0'X03(t) = 0' X11(t) = 0' X12(t) = 0'
X13(t) = 0, X21(t) = 0, X22(t) = 0, X23(t) = 0 and Y(t) = 0. These
assumptions allow a table of transition probabilities to be
constructed (not shown) that defines the mathematical structure of
the model.
Computer simulation
The stochastic simulation process used can be described as the
time-slice approach, in which the tumorigenic process is viewed as
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changing in all of its aspects over time. Its status is updated, in
units ofone cell cycle time, until a prescribed amount oftime has
elapsed. In our studies, we suppose the cell cycle time is not
influenced by the mutational events.
For normal stem cells and mutants, the distribution of the
number ofcells was computed without following the fate ofevery
cell: homogeneous populations of normal stem cells or mutants
were treated as groups. For such groups only the number of
cells were updated, using a multinominal random number gener-
ator, but using Poisson and normal random number generators to
provide approximation when the number of cells is very large.
Further details are given by Mao and Wheldon (1995). Malignant
cells that have arisen from normal stem cells are followed individ-
ually. Some samples are shown in Figure 8. This shows the occur-
rence of fluctuations in the growth pattern at small cell number,
due to the stochastic nature of both the growth and mutation
process. These fluctuations are smoothed out as the cell number
becomes larger.
The method for estimating the parameters in the models, which
involves matching the tumour-free survival distribution of the
experimental data with simulated data by a Monte Carlo method,
is as follows:
Partition the time interval [0, t] by I = [t. t.),j = 1, ... m-, and
Im = [tin t ], in which t. =j* At and m* At = t with t = t (in our 1,- m
studies, At = 7 days, m = 86). Let N. and n. be the number ofmice
that acquired tumour during I for the simulated and experimental
data respectively. The parameters are estimated by minimizing the
chi-square statistic
2m(Nj- ni)2 Nj= N.+n.
I J
In model 1, the values of the growth and death rate parameters
were prescribed by
0.564
bj(t)= 0.425e0231('-13) +0.139
d.(t) = 0.139 (j = 1,2, ...,k-l),
t< 13 days,
t 2 13 days,
and were chosen to provide reasonable growth kinetics for mouse
development from conception onwards. The same values were
used for models 2 and 3. The mutation rate was estimated to match
the tumorigenesis rate in wild-type mice.
Besides the mutation rate, in model 2, the fraction f of the
tumours developing by p53-mediated route in wild mice, and in
model 3, the modifier factor k, was estimated.
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